Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
RVNC Revance Therapeutics
33.130-0.750-2.21%
Close
01/27 16:00 ET
33.1300.0000.00%
Post Mkt Price 01/27 16:07 ET
High
33.980
Open
33.370
Turnover
24.32M
Low
32.881
Pre Close
33.880
Volume
728.84K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
HC Wainwright Increases Revance Therapeutics (NASDAQ:RVNC) Price Target to $42.00
Revance Therapeutics (NASDAQ:RVNC – Get Rating) had its price objective upped by investment analysts at HC Wainwright from $29.00 to $42.00 in a note issued to investors on Thursday, The Fly reports
Revance Therapeutics (NASDAQ:RVNC) Hits New 12-Month High Following Analyst Upgrade
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) shares reached a new 52-week high during mid-day trading on Thursday after HC Wainwright raised their price target on the stock from $29.00 to $4
Revance Therapeutics Price Target Raised to $42.00/Share From $29.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $42
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $29 to $42.
Revance Price Target Raised to $42 From $29 at H.C. Wainwright
Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and Revance Therapeutics (RVNC)
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $26 From $25, Maintains Equal-Weight Rating
10:43 AM EST, 01/24/2023 (MT Newswires) -- Revance Therapeutics (RVNC) has an average outperform rating and a price target range of $19 to $65, according to analysts polled by Capital IQ. Price: 33.66
Revance Therapeutics Price Target Raised to $26.00/Share From $25.00 by Morgan Stanley
Revance Therapeutics Price Target Raised to $26.00/Share From $25.00 by Morgan Stanley
Revance Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 -22.41% Morgan Stanley $25 → $26 Maintains Equal-Weight 01/10/2023 13.4% Needham $35 → $38 Main
Company Overview
More
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
CEO： Mr. Mark J. Foley
Market： NASDAQ
Listing Date： 02/06/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet